Is your organization missing from this list? Reach out to Leyla Cakici, Strategic Alliance Partnership Coordinator, to learn more about the complimentary strategic partnership program: lcakici@mjhlifesciences.com
Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit
Cadonilimab Plus Chemo Provides Survival Benefit in Gastric/GEJ Cancer
Lenvatinib Plus Pembrolizumab Improves Survival in Advanced/Recurrent Endometrial Cancer
Frontline Durvalumab Regimen Improves PFS, Responses in Advanced Endometrial Cancer